top
Please input keywords
新薬開発パイプライン
創造的技術による創薬で人々の健康を守る
バイオサイトジェンは患者様の必要を満たす創造的な抗体医薬品の開発に尽力しています。腫瘍、自己免疫、代謝、抗感染症など複数の疾患分野に特化し、独自の医薬品開発手法を十分に活用することにより、モノクローナル抗体、二重特異性抗体、抗体薬物複合体(ADC)など10を超える複数の開発パイプラインを有するに至りました。私たちは臨床開発チームと豊かな臨床リソースを駆使し、パイプラインの開発を推し進め、医薬品の臨床試験プロセスの加速を目指しています。
Therapeutic Area
Products
Target
Partner
Molecular Format
Indication
Status
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Oncology
YH003
CD40
Monoclonal Antibody
Solid Tumors
More
YH001
CTLA-4
Monoclonal Antibody
Solid Tumors
More
YH002
OX40
Monoclonal Antibody
Solid Tumors
More
YH004
4-1BB
Monoclonal antibody
More
YH005
Claudin18.2- ADC
Remegen
ADC
More
YH008
PD-1 x CD40
Bispecific antibody
More
YH006
CTLA-4 x OX40
Bispecific antibody
More
YH010
PD-L1 x IL12
Bispecific antibody
More
YH011
PD-L1 x cytokine
GeneQuantum
More
YH012
HER2 x TROP2
Bispecific ADC
More
YH013
EGFR x MET
Bispecific ADC
More
BCG003
TNFR2
Dragonboatbio
Monoclonal Antibody
Solid Tumors
BCG001
B7-H3
Mabworks
Monoclonal Antibody
Solid Tumors
BCG008
SIGLEC15
UNDISCLOSED
Monoclonal Antibody
Solid Tumors
BCG002
CD24
UNDISCLOSED
Monoclonal Antibody
Solid Tumors
BCG005
CCR8
LiberoThera
Monoclonal Antibody
Solid Tumors
BCG007
AMHR2
UNDISCLOSED
Monoclonal Antibody
Solid Tumors
Infectious Diseases
YH009
RSV
Monoclonal antibody
More
Oncology
YH003
More
Target:
CD40
Partner:
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH001
More
Target:
CTLA-4
Partner:
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH002
More
Target:
OX40
Partner:
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH004
More
Target:
4-1BB
Partner:
Molecular Format:
Monoclonal antibody
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH005
More
Target:
Claudin18.2- ADC
Partner:
Remegen
Molecular Format:
ADC
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH008
More
Target:
PD-1 x CD40
Partner:
Molecular Format:
Bispecific antibody
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH006
More
Target:
CTLA-4 x OX40
Partner:
Molecular Format:
Bispecific antibody
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH010
More
Target:
PD-L1 x IL12
Partner:
Molecular Format:
Bispecific antibody
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH011
More
Target:
PD-L1 x cytokine
Partner:
GeneQuantum
Molecular Format:
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH012
More
Target:
HER2 x TROP2
Partner:
Molecular Format:
Bispecific ADC
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH013
More
Target:
EGFR x MET
Partner:
Molecular Format:
Bispecific ADC
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG003
More
Target:
TNFR2
Partner:
Dragonboatbio
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG001
More
Target:
B7-H3
Partner:
Mabworks
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG008
More
Target:
SIGLEC15
Partner:
UNDISCLOSED
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG002
More
Target:
CD24
Partner:
UNDISCLOSED
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG005
More
Target:
CCR8
Partner:
LiberoThera
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG007
More
Target:
AMHR2
Partner:
UNDISCLOSED
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Infectious Diseases
YH009
More
Target:
RSV
Partner:
Molecular Format:
Monoclonal antibody
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
バイオサイトジェンは、すでに全世界の様々な製薬会社とRenMiceプラットフォームのライセンス契約と抗体医薬品の共同開発契約を締結しました。弊社との研究提携については下記リンクよりご確認ください。

パイプラインに関するお問い合わせはこちらへ: bd@eucure.com
研究提携